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Fracture risk among patients with urolithiasis: A population-based
cohort study. In a population-based retrospective cohort study, 624
Rochester, Minnesota residents with an initial symptomatic episode of
urolithiasis in 1950 to 1974 were followed for 11,909 person-years for
subsequent age-related fractures. During this period of observation, the
number of patients with a first vertebral fracture was over four times the
number expected on the basis of vertebral fracture incidence rates in the
general population of Rochester [standardized morbidity ratio (SMR),
4.3; 95% confidence interval, 3.4 to 5.3]. The risk of vertebral fracture was
elevated among men as well as women, and was associated with increasing
age and with the use of corticosteroids for more than six months.
However, vertebral fracture risk was increased nearly fourfold (SMR 3.9;
95% confidence interval, 3.0 to 4.9) among the urolithiasis patients
without such exposure, which suggests that corticosteroids do not com-
pletely account for the association with vertebral fractures. There was no
increase in the risk of hip, pelvis, proximal humerus or distal forearm
fractures in this cohort of patients, and their survival was not impaired.
Additional studies are needed to define the pathophysiology of vertebral
fractures among patients with urolithiasis.
Many medical and surgical conditions are important causes of
bone loss and fractures [1], and urolithiasis has long been
numbered among these disorders [2, 3]. Renal stones complicate
bone resorptive conditions and may also result from renal hyper-
calciuria, which has likewise been associated with reduced bone
density [4–6]. On the other hand, bone density may be normal
among urolithiasis patients with hyperabsorption of dietary cal-
cium [7, 8] who could thus be protected from osteoporotic
fractures. Most studies, however, have found only modest reduc-
tions in bone density among hypercalciuria patients generally [9].
To complicate matters further, some forms of urolithiasis therapy
involve efforts to lower dietary calcium intake, and reduced
calcium intake has been associated with bone loss [10, 11] as well
as an increased risk of fractures in some studies, though not others
[12–15]. Conversely, other types of therapy may lead to increased
serum calcium levels [16] and reduced bone demineralization [17].
Thiazide therapy, for example, has generally been associated with
increased bone density and a reduced risk of fractures [18]. To
date, there have been no population-based studies of fracture risk
following the initial diagnosis of urolithiasis that would allow the
practical implications of these diverse influences to be deter-
mined. The aim of the present study was to estimate the incidence
of age-related fractures among Rochester, Minnesota residents
first diagnosed with urolithiasis during the 25-year period of 1950
to 1974, and to compare this with the incidence in the general
population. In addition, we sought to evaluate the impact of other
risk factors for fracture, which may be independent and/or
additive to the effects of kidney stones.
METHODS
Population-based epidemiologic research can be conducted in
Rochester because medical records for the entire population are
available from almost all providers of care. Most of the endocri-
nological, surgical and trauma care is provided by the Mayo
Clinic, which has maintained a common medical record with its
two large affiliated hospitals (St. Marys and Rochester Methodist)
for 90 years. This dossier-type record contains both inpatient and
outpatient data, and the diagnoses and surgical procedures re-
corded in these records are entered into a computerized index
[19]. Medical records of the other providers who serve the local
population, most notably the Olmsted Medical Group and its
affiliated Olmsted Community Hospital, are indexed into the
same system (the Rochester Epidemiology Project) and are also
available for study [20]. Using this unique database, 672 Roches-
ter residents were identified who presented with their first episode
of symptomatic (renal colic, hematuria, dysuria) urolithiasis in the
time period of 1950 to 1974, as described in detail elsewhere [21].
Patients with asymptomatic stones found incidentally or those
who presented primarily for urinary tract infections were not
included. For the present analysis, we excluded five patients who
had only possible rather than probable or definite renal stones and
three patients who died within 30 days of their first episode of
urolithiasis. We excluded an additional 32 patients who, upon
further review, were found to have exclusions (infection, staghorn
calculus), and 8 with an earlier episode of urolithiasis prior to
1950 or before immigrating to Rochester. Thus, the final study
population numbered 624 individuals.
These subjects were then followed forward in time through
their linked medical records in the community (retrospective
cohort study) until death or the most recent clinical contact. For
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each subject, all inpatient and outpatient medical records at any
local provider of health care were searched for the occurrence of
specific fractures. Mayo Clinic records, for example, contain the
details of every inpatient hospitalization at its two hospitals, every
outpatient office or clinic visit, emergency room and nursing home
care, as well as radiographic reports and pathology reports,
including autopsies [19]. Emphasis was on fractures at the skeletal
sites usually associated with osteoporosis, and these were re-
corded regardless of whether they occurred before or after the
recognition of urolithiasis. The records contained the clinical
history and the radiologist’s report of each fracture, but the
original roentgenograms were not available for review. Thus, the
diagnosis of vertebral fracture was accepted on the basis of a
radiologist’s report of compression or collapse of one or more
thoracic or lumbar vertebrae. All fractures were classified accord-
ing to the circumstances of the injury. By convention, falls from
standing height or less were considered moderate trauma, while
motor vehicle accidents and falls from heights were deemed
severe trauma. Ascertainment of the fractures of interest is
believed to be complete except for vertebral fractures, some of
which are never diagnosed [22].
The influence of urolithiasis on fracture incidence was evalu-
ated using three basic methods of analysis. In the primary analysis,
we calculated standardized morbidity ratios (SMRs), comparing
the number of fractures that were observed at the selected skeletal
sites (based on the first fracture of a given type per person) to the
number expected in this cohort during their follow-up in the
community. Patients were deleted from the analysis for specific
fracture sites who had experienced that particular type of fracture
after the age of 35 years but prior to the initial recognition of
urolithiasis. Expected numbers of fractures were derived by
applying age- and sex-specific incidence rates from the general
population for these fractures to the age- and sex-specific person-
years of follow-up in the cohort. Incidence rates from the general
population of Rochester were available for fractures of the
proximal femur [23], distal forearm [24], proximal humerus [25],
pelvis [26] and vertebrae [22]. Ninety-five percent confidence
intervals for the SMRs were calculated assuming that the ex-
pected rates are fixed and the observed fractures follow a Poisson
distribution [27].
In the second method of analysis, the cumulative incidence of
new fractures (1 minus survival-free-of-fracture) was projected for
up to 30 years following the index date, using product-limit life
table methods [28]. Cumulative incidence curves were compared
using the log-rank test statistic [29]. Product-limit life table
methods were also used to assess survival, with expected death
rates derived from Minnesota whites of like age and gender.
Finally, the relative influence of various clinical characteristics
on subsequent fracture risk was evaluated with proportional
hazards models [30], using chi-square tests for the coefficients of
the models and for the model likelihood ratio. Univariate rela-
tionships between the risk of any fracture due to moderate
trauma, as well as any fracture of a specific type, and each clinical
characteristic under consideration were first assessed. Stepwise
methods with forward selection and backward elimination were
then used to choose independent variables for the final model.
The dependent variable was time until the first new fracture, and
the independent variables were age, sex and the clinical charac-
teristics. Drug exposures were measured as time-dependent vari-
ables. For the final multiple models, as well as for the univariate
models, the assumption of proportional hazards was examined
and was not violated for the variables considered.
RESULTS
Six hundred twenty-four Rochester, Minnesota residents were
first recognized with symptomatic urolithiasis in the 25-year study
period and met the criteria for inclusion in this analysis. Of the
total, 442 (71%) were men. The patients ranged in age from 12 to
92 years, with a median age at first diagnosis of 43.4 years (mean
44.3 years). All but four of the patients were white, reflecting the
racial composition of the community. The majority of patients
were diagnosed clinically (including plain films of the abdomen,
excretory urograms and cystoscopy), and the type of stone was not
established (Table 1). Of the 227 patients whose stones were
evaluated, nearly 70% were calcium oxalate and 20% more were
of mixed type, mostly calcium oxalate with phosphate or carbon-
ate. Likewise, urolithiasis was ascribed to a particular etiology in
less than one-third of the patients, mostly hyperuricemia followed
by idiopathic hypercalciuria and hyperparathyroidism (Table 1). It
was not possible to apply contemporary diagnostic criteria to
patients evaluated over two decades ago, but none of the cases
was attributed by their attending physicians to absorptive hyper-
calciuria or renal tubular acidosis. Among these unselected pa-
tients from the community, only 22 were begun on chronic
medical therapy following this initial symptomatic episode (allo-
purinol therapy in 10, alkalinization of the urine in 9, neutral
phosphate in 2 and probenecid for one patient with uric acid
stones). Subsequently, a few others were treated with pharmaco-
therapy for urolithiasis (11 with neutral phosphate but none with
sodium cellulose phosphate), despite the fact that 38% of the total
group had at least one recurrent stone episode. However, 192 of
the remaining 591 patients were on thiazide diuretics during
follow-up and 22 were taking calcium supplements, although we
could not link treatment specifically with their kidney stones. We
made no attempt to document general recommendations with
respect to changes in diet or fluid intake.
Following the initial recognition of urolithiasis, the cohort was
followed for a total of 13,034 person-years for vital status, during
which time 230 subjects died. Survival was slightly better (P 5
0.019) than that expected for individuals of similar age and sex
Table 1. Characteristics of Rochester, Minnesota residents with
symptomatic urolithiasis first recognized in 1950 to 1974
N %
Type of stone
Calcium oxalate 158 25.3
Calcium phosphate 15 2.4
Mixed 45 7.2
Urate 8 1.3
Other 1 0.2
Unknown 397 63.6
Clinical diagnosisa
Hyperuricemia/gout 146 23.4
Idiopathic hypercalciuria 47 7.5
Hyperparathyroidism 13 2.1
Small bowel resection 9 1.4
Inflammatory bowel disease 4 0.6
Sarcoidosis 1 0.2
Uncertain 428 68.6
a More than one diagnosis may have been reported
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from the general population as shown in Figure 1. Follow-up for
fractures was only through the date of the last clinic visit and
totaled 11,909 person-years (mean, 19.1 years per subject 6 11.5
years). Median follow-up was 19.8 years for those who died, 23.5
years for those who survived at last follow-up and 21.3 years
overall. Seventy percent of the survivors had been seen within five
years of the time of data collection, thus indicating a relatively
stable study population. During this period of observation, 122
subjects suffered one or more of the fractures of interest. The
distribution of causes by fracture site is delineated in Table 2. The
majority of limb fractures were due to falls from a standing height
or less, while most of the vertebral fractures occurred “spontane-
ously” in the course of the activities of daily living. Fracture risk
increased steadily with time, reaching 16% by 20 years and 33% by
30 years following the initial episode of symptomatic urolithiasis.
Because 54 of the women (30%) had one or more of these
fractures compared to 68 of the men (15%), the cumulative
incidence was greater among women (Fig. 2). At 30 years, the
cumulative incidence was estimated at 45% for the women and
only 28% for the men.
Deleting 21 individuals who had a vertebral fracture prior to
their first symptomatic episode of urolithiasis, the risk of a
subsequent vertebral fracture was increased over fourfold above
that expected for Rochester residents generally (Table 3). The
standardized morbidity ratio was relatively higher among the men
(SMR 7.0; 95% CI 5.3 to 9.2) than the women (SMR 2.4; 95% CI
1.6 to 3.5), although both were statistically significantly increased.
This is also reflected in the cumulative incidence of vertebral
fracture in this cohort (Fig. 3), which was 25% at 30 years
compared to an expected 6% (P , 0.001). Compared to that
expected, fracture risk was not elevated at the proximal humerus
(deleting 4 subjects with a prior proximal humerus fracture), the
distal forearm (deleting 11 subjects with a prior distal forearm
fracture), the pelvis (deleting 2 subjects with a prior pelvic
fracture) or the proximal femur (deleting 3 subjects with a prior
hip fracture) either in men, women or both sexes combined (Table
3).
In a multivariate analysis (Table 4), increasing age [hazard ratio
(HR) per 10-year increase, 1.9; 95% CI 1.6 to 2.2] and female
gender (HR 2.4; 95% CI 1.6 to 3.5) were independent predictors
of the risk of any moderate trauma fracture (excluding fractures
due to severe trauma and specific pathologies), as would be
expected. However, corticosteroid use for more than six months
was also an independent risk factor in the multivariate analysis
(HR 3.6; 95% CI 1.7 to 7.6). Twenty-four patients had long-term
corticosteroid exposure, while 26 others who were exposed for a
shorter period of time (mean 1.8 months) were not included.
Prednisone was used in the majority of cases and was indicated for
a wide variety of conditions (arteritis in 5, chronic obstructive
pulmonary disease in 5, asthma in 3, rheumatoid arthritis in 2,
polymyalgia rheumatica in 2, transplantation in 2, and miscella-
neous other conditions in 5). However, corticosteroid use mainly
influenced the risk of vertebral fractures (see below). When
vertebral fractures were excluded from the analysis, long-term
corticosteroid use was not an independent predictor of the risk of
limb fractures due to moderate trauma. For all fractures together,
recurrent stones (yes vs. no) documented in 235 patients (HR 0.6;
95% CI 0.4 to 0.9) and moderate alcohol use (versus not) in 457
patients (HR 0.4; 95% CI 0.3 to 0.6) were protective in the
univariate analysis (Table 4). Neither thiazide use (HR 1.4; 95%
CI 0.99 to 2.1) nor calcium supplementation (HR 1.8; 95% CI 0.2
to 1.5) was associated with any reduction in fracture risk. A risk
factor score that counted the number of diseases associated with
secondary osteoporosis (seen in 39 patients), along with several
protective conditions, was associated with an increased risk of
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Fig. 1. Observed (solid line) and expected (dashed line) survival follow-
ing the initial episode of symptomatic urolithiasis among Rochester,
Minnesota, residents, 1950 to 1974.
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Fig. 2. Cumulative incidence of any new age-related fracture among
Rochester, Minnesota men (dashed line) and women (solid line) following
the initial episode of symptomatic urolithiasis, 1950 to 1974.
Table 2. Fractures by skeletal site and cause among Rochester,
Minnesota residents following the initial episode of symptomatic
urolithiasis, 1950 to 1974
Cause
Fracture site
Vertebra
Proximal
humerus
Distal
forearm Pelvis
Proximal
femur
Motor vehicle accident 5 1 2
Fall from height 5 3 3 1 2
Fall from standing 7 9 19 2 15
Other trauma 5
Spontaneous 57 1 1 2
Pathological 2
Unknown 5 1 1
Total 86 14 23 7 19
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fracture (HR 1.5; 95% CI 1.1 to 1.9) in the univariate analysis.
None of these factors was an independent predictor of fracture
risk in the multivariate analysis, however. A history of hyperuri-
cemia or gout was not a significant risk factor for fracture in the
univariate model, but was significant after adjusting for age and
gender, and was an independent predictor of fracture risk in the
multivariate model (HR 0.6; 95% CI 0.4 to 0.9). The protective
effect of hyperuricemia was not accounted for by adjustment for
body mass index.
For vertebral fractures alone, and including all subjects in the
analysis, age was a risk factor (HR per 10-year increase, 1.8; 95%
CI 1.6 to 2.2) as indicated in Table 5, but gender was no longer a
predictor (P 5 0.67). The only other independent risk factor was
corticosteroid use for more than six months (HR 4.6; 95% CI 2.2
to 9.6). When the 24 patients on long-term corticosteroids were
excluded, however, the standardized morbidity ratio for vertebral
fractures was still elevated (SMR 3.9; 95% CI 3.0 to 4.9),
indicating that corticosteroid use did not account for all of the
excess of vertebral fractures observed in this cohort. In the
univariate analysis for vertebral fractures (Table 5), recurrent
stones (HR 0.6, 95% CI 0.4 to 0.95) and alcohol use (HR 0.6; 95%
CI 0.4 to 0.98) were protective, but neither was an independent
predictor of vertebral fracture risk in the multivariate analysis.
DISCUSSION
The present investigation was based on an inception cohort
comprised of all community residents who came to clinical
attention during the study period with their first symptomatic
stone episode. These patients were unselected, other than the
necessity of clinical diagnosis, and 51% were attended only as
outpatients [21]. As a consequence, most of the stones were not
analyzed, and an underlying diagnosis was firmly established in a
minority of patients. In this cohort, there was no association with
distal forearm fractures, in keeping with the results of a case-
control study of forearm fractures in Uppsala, Sweden [31].
Urolithiasis was not associated with the risk of distal forearm
fractures among Swedish men (odds ratio 1.0; 95% CI 0.2 to 4.1);
the risk among Swedish women (odds ratio 1.1; 95% CI 0.4 to 3.2)
was identical to that reported here for Rochester women and
neither result was statistically significant. Only 3% of the Swedish
patients with a distal forearm fracture had a history of urolithiasis
[31]. Likewise, the 50% reduction in hip fracture risk among
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Fig. 3. Observed (solid line) and expected (dashed line) cumulative
incidence of vertebral fractures among Rochester, Minnesota, residents
following the initial episode of symptomatic urolithiasis, 1950 to 1974.
Table 3. Observed (Obs) fractures after the index date at selected sites in comparison with expected numbers (Exp) and standardized morbidity
ratios (SMRs) among Rochester, Minnesota residents following the initial episode of symptomatic urolithiasis, 1950 to 1974
Fracture site
Men Women Both sexes
Obs Exp SMR 95% CI Obs Exp SMR 95% CI Obs Exp SMR 95% CI
Vertebra 54 7.68 7.0 5.3–9.2 27 11.16 2.4 1.6–3.5 81 18.84 4.3 3.4–5.3
Proximal humerus 6 4.46 1.4 0.5–2.9 8 5.60 1.4 0.6–2.8 14 10.06 1.4 0.8–2.3
Distal forearm 7 10.10 0.7 0.3–1.4 15 13.18 1.1 0.6–1.9 22 23.28 1.0 0.6–1.4
Pelvis 3 2.69 1.1 0.2–3.2 2 3.37 0.6 0.1–2.1 5 6.06 0.8 0.3–1.9
Proximal femur 5 9.83 0.5 0.2–1.2 14 12.57 1.1 0.6–1.9 19 22.40 0.8 0.5–1.3
Table 4. Proportional hazards modelsa for the development of any age-
related fracture due to moderate trauma among Rochester, Minnesota,
residents following the first episode of symptomatic urolithiasis, 1950 to
1974
Factor
Univariate Multivariate
N b SEb P b SEb P
Age 624 0.0643 0.0080 ,0.001 0.0629 0.0079 ,0.001
Female gender 624 0.9770 0.1984 ,0.001 0.8661 0.2019 ,0.001
Corticosteroid
use
624 1.3296 0.3736 ,0.001 1.2744 0.3811 0.003
Recurrent stones 624 20.5467 0.2098 0.009
Alcohol
consumption
587 20.9330 0.2113 ,0.001
Risk factor scoreb 624 0.3705 0.1344 ,0.006
Hyperuricemia/
gout
624 20.0692 0.2175 0.75 20.5615 0.2266 0.013
a Event is any age-related fracture; dependent variable is survival time
(days) free of any age-related fracture.
b Risk factors that were observed included Paget’s disease, renal failure,
insulin-dependent diabetes, hyperparathyroidism, hyperthyroidism, thy-
roidectomy, gastric resection, chronic obstructive pulmonary disease,
asthma, hemiplegia or hemiparesis, lower extremity disuse and malig-
nancy. Non-insulin dependent diabetes, hypothyroidism and moderate
alcohol use were considered protective.
Table 5. Proportional hazards modelsa for the development of a
vertebral fracture among Rochester, Minnesota, residents following the
first episode of symptomatic urolithiasis, 1950 to 1974
Factor
Univariate Multivariate
N b SEb P b SEb P
Age 624 0.0611 0.0087 ,0.001 0.0613 0.0089 ,0.001
Corticosteroid use 624 1.6280 0.3772 ,0.001 1.5218 0.3766 ,0.001
Recurrent stones 624 20.5000 0.2283 0.028
Alcohol use 587 20.5018 0.2441 0.040
a Event is any vertebral fracture; dependent variable is survival time
(days) free of any vertebral fracture
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Rochester men with urolithiasis, though not statistically signifi-
cant, was consistent with an earlier case-control study in this
community showing that urolithiasis was associated with a de-
creased risk of hip fracture among Rochester men (odds ratio 0.4;
95% CI 0.2 to 0.8); only about 5% of 232 Rochester men with a
moderate trauma hip fracture had a history of urolithiasis com-
pared to 10% of a comparable group of control men [32].
However, no reduction in hip fracture risk was seen among the
women with urolithiasis in the present study. Nearly a third of the
cohort were prescribed thiazide diuretics at some point, and one
might have expected some reduction in hip fracture risk on this
basis [18]. There were not enough hip fractures to support a
reliable analysis, but use of thiazide diuretics was not associated
with any reduction in overall fracture risk in this cohort.
There was a substantial increase in the risk of vertebral
fractures among Rochester residents with urolithiasis. This is
consistent with the suggestion that there is a greater deficit of
bone density at the spine than the hip in patients with nephroli-
thiasis [11]. Rather surprisingly, two-thirds of these fractures were
in men, who account for only one-fourth of all vertebral fracture
patients in the community [22]. In an earlier case-control study of
vertebral fractures in men, however, no association with kidney
stones was found [33]. Other than age, the only independent
predictor of vertebral fractures in this study was a history of
substantial corticosteroid use. This finding is not surprising since
corticosteroid therapy may lead both to loss of predominantly
cancellous bone [34, 35] and to renal hypercalciuria [36]. How-
ever, even excluding the cases of corticosteroid use, a history of
nephrolithiasis still increased the risk of vertebral fracture, indi-
cating an independent effect of stone disease on vertebral fracture
risk. A defect in calcium absorption is aggravated by low dietary
calcium intake in some patients on corticosteroids [37], and there
has been concern that long-term low calcium diets, themselves,
might have adverse skeletal effects in patients with urolithiasis
[38]. In the case of patients with vertebral fractures specifically,
there is evidence that calcium absorption is impaired [39–42], but
the relative contribution of low calcium intake to fracture risk in
this group has not been rigorously assessed. In a trial among
patients with calcium stones due to renal hypercalciuria, however,
dietary calcium restriction was associated with an increase in bone
turnover [5], and elevated bone turnover has been shown to be an
independent risk factor for vertebral fractures [43]. It was not
possible to assess bone turnover in a medical records study such as
this, but it seems clear that more research is needed into the
causes of bone loss in these patients and, particularly, with respect
to the potential for corticosteroid therapy to aggravate reduced
osteoblast function in these patients [9].
Hyperparathyroidism has long been associated with renal
stones, but this is uncommon among the patients diagnosed in
recent decades, who typically are discovered incidentally by virtue
of elevated serum calcium levels [44]. Patients with mild hyper-
parathyroidism also appear to be at no increased risk of osteopo-
rosis or fractures [1], although vertebral fracture risk may be
increased among more severely affected patients [45, 46]. A
diagnosis of hyperparathyroidism was not associated with an
increased risk of fracture in this study, but only 13 subjects were
thought to have urolithiasis on this basis, which is consistent with
other recent series [47, 48]. Much more common was a history of
hyperuricemia or gout found in 146 patients. This is comparable
to the proportion of patients with hyperuricosuria reported in
clinical series [49, 50]. Among the latter patients, there was a
reduction in the risk of limb fractures that was statistically
significant after adjusting for gender and age that persisted in the
multivariate analysis even after adjusting for body mass index.
Although not designed to evaluate pathogenetic mechanisms,
this study provides the best empirical evidence to date that
fracture risk is increased among patients with kidney stones.
However, the increased risk is confined to vertebral fractures and
is accounted for, in part, by the adverse influence of corticosteroid
use. Low calcium intake could also be a risk factor, although we
could not evaluate this possibility directly. Since low calcium
intake is associated with an increased rather than decreased risk
of kidney stones [51], it may be unwise to restrict dietary calcium
among patients with urolithiasis, especially if the negative effects
of corticosteroids on the skeleton are augmented by low calcium
intake. More data are needed to resolve this issue. Excessive
protein intake has also been associated with the development of
stones [52] and with low bone mass [53], but we found little
association of dietary protein intake with bone mineral density of
the lumbar spine in a separate study of women from the general
Rochester population [54]. It does seem clear that specific phar-
macotherapy for urolithiasis is not responsible for the increased
risk of vertebral fractures seen here, since pharmacotherapy was
not an independent predictor in the analysis and because only a
small minority of patients in this community-based cohort were so
treated.
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